RecruitingNot Applicable

A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

South Korea3,000 participantsStarted 2025-08-27

Plain-language summary

The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Frequency and proportion of AEs/ADRs

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of unexpected AEs/ADRs

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of SAEs/SADRs

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of AESI

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Trial details

NCT IDNCT07152119

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-03-23

Contact for this trial

Pfizer CT.gov Call Center

1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

View on ClinicalTrials.gov More Severe Alopecia Areata trials

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Frequency and proportion of AEs/ADRs

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of unexpected AEs/ADRs

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of SAEs/SADRs

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of AESI

Timeframe: 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)